Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,439 stopped studies mapped to Adenocarcinoma and descendants · 92% state a reason
Over the 1,439 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT06586658 | Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or… | Early Phase 1 | suspended | Sep 19, 2024 | Shanghai Changzheng Hospital | Modifications to the trial design | Other (stated, no rule matched) |
| NCT05689021 | CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate… | Phase 2 | terminated | Jan 18, 2023 | Mayo Clinic | Sponsor decided to close due to slow accrual and lack of efficacy | Efficacy / futility |
| NCT06528093 | A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With… | Phase 1 | terminated | Jul 30, 2024 | Boehringer Ingelheim | not stated | Not stated |
| NCT06538389 | High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced… | Phase 2 | suspended | Aug 5, 2024 | City of Hope Medical Center | Accrual goal met | Enrollment / accrual |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2022 | TCR2 Therapeutics | No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear… | Enrollment / accrual |
| NCT04331067 | Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast… | Phase 1 / Phase 2 | terminated | Apr 2, 2020 | Washington University School of Medicine | BMS terminated the study | Other (stated, no rule matched) |
| NCT05705791 | Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial…(HOLMBRAVE) | N/A | terminated | Jan 31, 2023 | Gustave Roussy, Cancer Campus, Grand Paris | Toxicities | Safety / toxicity |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… | Phase 1 | terminated | Sep 5, 2024 | BeOne Medicines | The Sponsor has made the decision to terminate this study due to the lack of promising efficacy,… | Efficacy / futility |
| NCT04216472 | Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple… | Phase 2 | terminated | Jan 2, 2020 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06466187 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Phase 1 | terminated | Jun 20, 2024 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT04809766 | Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic… | Phase 1 | terminated | Mar 22, 2021 | Fred Hutchinson Cancer Center | Study terminated due to end of funding. | Funding |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating… | Phase 2 | terminated | Jun 6, 2013 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT04273555 | Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients… | Phase 1 / Phase 2 | withdrawn | Feb 18, 2020 | University of Alabama at Birmingham | Unable to recruit for this study. | Enrollment / accrual |
| NCT05967533 | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With… | Phase 1 | suspended | Aug 1, 2023 | University of California, Davis | For internal interim analysis | Efficacy / futility |
| NCT05101356 | A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab… | Phase 1 / Phase 2 | suspended | Nov 1, 2021 | University of California, Davis | Drugs unavailable | Other (stated, no rule matched) |
| NCT07136493 | Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With… | N/A | withdrawn | Aug 22, 2025 | City of Hope Medical Center | Funding This study has been closed at City of Hope at the request of the Sponsor due to delays and… | Funding |
| NCT03630640 | Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation(NIVOLEP) | Phase 2 | terminated | Aug 15, 2018 | Assistance Publique - Hôpitaux de Paris | Because patient recruitment was affected by the COVID-19 pandemic, the study sponsor and funding… | COVID-19 / pandemic |
| NCT04975516 | Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for… | Phase 2 | terminated | Jul 23, 2021 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT05514717 | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Phase 1 | terminated | Aug 24, 2022 | Day One Biopharmaceuticals, Inc. | Development discontinued. | Other (stated, no rule matched) |
| NCT05537402 | LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC(LOST-B) | Phase 2 | terminated | Sep 13, 2022 | University of Texas Southwestern Medical Center | The decision was made to close the study to enrollment due to poor overall accrual and the… | Enrollment / accrual |
| NCT02626312 | Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma,… | Phase 1 | terminated | Dec 10, 2015 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT06902246 | Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma | Phase 2 | withdrawn | Mar 30, 2025 | University of Miami | Investigator decision | Investigator |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In… | Phase 2 | terminated | Jun 7, 2021 | Regeneron Pharmaceuticals | Sponsor Decision related to study drug supply | Drug supply |
| NCT04955743 | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal… | Phase 2 | terminated | Jul 9, 2021 | Yale University | Lack of activity in the drugs | Other (stated, no rule matched) |
| NCT05183828 | Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer | Phase 4 | terminated | Jan 11, 2022 | University of Washington | Study ended earlier than anticipated due to end of funding. | Funding |
| NCT05419479 | Switch Maintenance in Pancreatic | Phase 1 / Phase 2 | suspended | Jun 15, 2022 | James Cleary, MD, PhD | Efficacy concerns. | Efficacy / futility |
| NCT06351332 | ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC | Phase 1 | terminated | Apr 8, 2024 | Filipa Lynce, MD | Zentalis terminated contract due to concern for toxicity safety from previously reported serious… | Safety / toxicity |
| NCT05275075 | Identify microRNAs in Cachexia in Pancreatic Carcinoma(SCC-miRPanCa) | — | terminated | Mar 11, 2022 | University of Oklahoma | Translational scientist left university | Other (stated, no rule matched) |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Dec 15, 2023 | Genmab | Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk… | Other (stated, no rule matched) |
| NCT03199885 | Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive… | Phase 3 | terminated | Jun 27, 2017 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT06405061 | Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and… | Phase 2 | suspended | May 8, 2024 | Tianjin Medical University Cancer Institute and Hospital | Mid-term data analysis for the project has been completed; enrollment is now suspended. | Enrollment / accrual |
| NCT06878248 | A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast… | Phase 1 | terminated | Mar 14, 2025 | Calibr, a division of Scripps Research | Business Decision | Sponsor / business decision |
| NCT06391099 | Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With… | N/A | suspended | Apr 30, 2024 | Ohio State University Comprehensive Cancer Center | pending amendment | Other (stated, no rule matched) |
| NCT04975217 | Fecal Microbial Transplants for the Treatment of Pancreatic Cancer | Early Phase 1 | suspended | Jul 23, 2021 | M.D. Anderson Cancer Center | PI request | Other (stated, no rule matched) |
| NCT04588246 | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to… | Phase 3 | terminated | Oct 19, 2020 | NRG Oncology | Inadequate accrual rate | Enrollment / accrual |
| NCT06844669 | HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving… | Phase 2 | terminated | Feb 25, 2025 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT02928627 | Clinical Significance of Hepatic and Circulating microRNAs miR-221 and miR-222 in… | — | terminated | Oct 10, 2016 | University of Aberdeen | The project did not progress as there were no findings available for the lab analysis of microRNA… | Other (stated, no rule matched) |
| NCT05200442 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | Phase 1 / Phase 2 | suspended | Jan 20, 2022 | University of Chicago | enrollment goal met pending determination of evaluable subjects | Enrollment / accrual |
| NCT06708936 | KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory… | Early Phase 1 | withdrawn | Nov 29, 2024 | Kousai Bio Co., Ltd. | Due to a strategic adjustment, the company has decided to terminate the project. | Sponsor / business decision |
| NCT06653023 | Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer(Wondercel-UWD3) | Early Phase 1 | suspended | Oct 22, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT05027425 | Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed… | Phase 2 | terminated | Aug 30, 2021 | University of Cincinnati | The study is closing due to low enrollment and feasibility of the study. | Enrollment / accrual |
| NCT06617455 | Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking…(VEnT) | Phase 2 | terminated | Sep 27, 2024 | University of Michigan Rogel Cancer Center | Lack of Patient Interest | Other (stated, no rule matched) |
| NCT02908048 | Extracellular RNA Markers of Liver Disease and Cancer | — | terminated | Sep 20, 2016 | Mayo Clinic | Ran out of funds | Funding |
| NCT04034251 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for… | Phase 2 | terminated | Jul 26, 2019 | National Cancer Institute (NCI) | Scientific reprioritization. Closed per principal investigator discretion to prioritize enrollment… | Investigator |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2023 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT02072616 | Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.(CTC-Pancreas) | N/A | terminated | Feb 26, 2014 | University Hospital, Rouen | Analysis not possible at the stage | Other (stated, no rule matched) |
| NCT03738553 | Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy | — | terminated | Nov 13, 2018 | University of Washington | Study closed to accrual after meeting grant enrollment goal, prior to reaching protocol accrual… | Enrollment / accrual |
| NCT04481204 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or… | Phase 2 | withdrawn | Jul 22, 2020 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT05755269 | Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African… | — | terminated | Mar 6, 2023 | Mayo Clinic | Lack of funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 23, 2026source: clinicaltrials